---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014620"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T15:57:10.533192+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# BioCardia initiates patient enrollment at University of Wisconsin for CardiAMP HF II Phase 3 trial

## Summary
- University of Wisconsin now enrolling ischemic HFrEF patients in BioCardia's pivotal Phase 3 CardiAMP HF II trial.
- Dr. Amish Raval named site PI and co-national PI for the study.
- Trial uses autologous cell therapy with a three-tier composite outcome: death, nonfatal MACE, and quality-of-life.
- Prior CardiAMP HF study met composite endpoint in elevated NTproBNP patients (p=0.02).
- Advances include cell population analysis for dosing and FDA-approved Morph DNA steerable platform.

## SEC filing metadata
- accession: 0001437749-25-014620
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925014620/0001437749-25-014620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925014620/bcda20250505_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014620
- JSON: https://secwatch.observer/filing/0001437749-25-014620.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.